Back to Dashboard
16 Sources
#trending
#stock_market
Sun Pharma Q3 Results: Cons PAT jumps 16% YoY to Rs 3,369 crore; Rs 11/share interim dividend declared
Sun Pharma posted a strong Q3FY26 performance with net profit up 16% and revenue rising 13%. EBITDA surged 23% as margins expanded to 31.9%. Growth was broad-based across India, emerging markets and RoW, while the US business remained steady. The company also declared an interim dividend of Rs 11 per share.
Sources: Economic Times - Markets (English), Hindu, NDTV +13 more
AI Content Studio
Powered by Gemini
New Project